Ironwood Non Current Liabilities Total from 2010 to 2024
| IRWD Stock | USD 3.35 0.09 2.62% |
Non Current Liabilities Total | First Reported 2008-12-31 | Previous Quarter 671.8 M | Current Value 211.7 M | Quarterly Volatility 193.3 M |
Check Ironwood Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ironwood Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 19.9 M or Total Revenue of 231.7 M, as well as many indicators such as Price To Sales Ratio of 3.82, Dividend Yield of 0.0 or Days Sales Outstanding of 142. Ironwood financial statements analysis is a perfect complement when working with Ironwood Pharmaceuticals Valuation or Volatility modules.
Ironwood | Non Current Liabilities Total |
Latest Ironwood Pharmaceuticals' Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Ironwood Pharmaceuticals over the last few years. It is Ironwood Pharmaceuticals' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Ironwood Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Ironwood Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 352,288,593 | |
| Geometric Mean | 274,504,482 | |
| Coefficient Of Variation | 48.48 | |
| Mean Deviation | 137,076,129 | |
| Median | 408,897,000 | |
| Standard Deviation | 170,795,678 | |
| Sample Variance | 29171.2T | |
| Range | 521.1M | |
| R-Value | 0.65 | |
| Mean Square Error | 18126.9T | |
| R-Squared | 0.42 | |
| Significance | 0.01 | |
| Slope | 24,838,562 | |
| Total Sum of Squares | 408396.3T |
Ironwood Non Current Liabilities Total History
About Ironwood Pharmaceuticals Financial Statements
Ironwood Pharmaceuticals stakeholders use historical fundamental indicators, such as Ironwood Pharmaceuticals' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Although Ironwood Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ironwood Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ironwood Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ironwood Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 541.3 M | 370.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.01) | Revenue Per Share 2.393 | Quarterly Revenue Growth (0.20) | Return On Assets 0.1305 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.